Psoriasis is a chronic, recurrent, inflammatory and systemic disease, which places a heavy burden on patients and affects their quality of life. As multiple biologics have been constantly approved for clinical use, there are more effective treatment options for psoriasis patients, but there has been no consensus on what are the comprehensive treatment goals to be reached in China. Treat-to-target approach requires considering treatment outcomes in multiple dimensions, establishing long-term management goals, and assessing treatment outcomes regularly. Based on the latest Chinese and international consensus and guidelines, studies and clinical experience, and combined with results of a questionnaire survey and expert group discussion, this consensus focuses on the short-term and long-term comprehensive management goals on biologics treatment of psoriasis in four dimensions, i.e., clearing psoriatic lesions, improving the quality of life, screening and managing psoriasis comorbidities, and ensuring medication safety, and describes implementation methods, timing of evaluation, treatment monitoring, and regimen adjustment, aiming to achieve the goal of comprehensive management of psoriasis to the greatest extent, and to provide a reference for clinicians.

Psoriasis; Biological agents; Treat-to-target; Comorbidity; Consensus